Acadia Pharmaceuticals 2025 Q3 Earnings Record Net Income Surges 119%

Acadia Pharmaceuticals (ACAD) delivered a standout performance in Q3 2025, . The company’s results underscore strong product demand and operational execution.

Revenue

, . The growth was driven entirely by product sales, . This performance highlights robust demand for the company’s flagship products, NUPLAZID and DAYBUE, and successful market expansion efforts.

Earnings/Net Income

, . This marks the highest quarterly net income in over two decades, underscoring Acadia’s strengthening profitability and operational efficiency.

Post-Earnings Price Action Review

, . This positive trend suggests investor confidence in Acadia’s revenue growth, driven by product demand and market expansion. The 30-day holding period balances risk and reward, making it a viable strategy for capitalizing on company-specific momentum.

CEO Commentary

CEO emphasized Acadia’s Q3 success, . Adams highlighted accelerated new prescriptions and expanded field force efforts, expressing optimism about surpassing $1 billion in 2025 sales. Strategic priorities include advancing pipeline candidates like ACP-204 and trofinetide, as well as leveraging leadership roles in industry organizations.

Guidance

, . , . The updated guidance reflects expanded revenue from non-U.S. named patient programs and tax benefits from the One Big Beautiful Bill Act.

Additional News

Acadia announced key leadership changes, including appointing as Senior Vice President and Chief Business and Strategy Officer. Katcheves brings expertise in global business development to accelerate pipeline expansion. Additionally, Catherine Owen Adams was named Chairperson of the section, reinforcing Acadia’s commitment to industry leadership. The company also initiated a Phase 2 trial for ACP-204 in Lewy Body Dementia Psychosis and a Phase 3 trial for trofinetide in Rett syndrome in Japan, signaling progress in its clinical pipeline.